The goal of this study is to evaluate how safe and effective the new drug neflamapimod is for the treatment of participants with dementia with Lewy bodies (DLB). The study compares the effect of the new drug neflamapimod with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug are capsules that you take with food.
Dementia with Lewy bodies
Study days are spread over 21 to 55 weeks
Amsterdam, Den Bosch or Zwolle